Hemgenix - The emergence of 10-Year Innovative Contracting agreements in Europe : IC Fireside Chats - Episode 17
What happens when a one-time therapy offers a lifetime of benefit — but payers still expect year-by-year value?
Hemgenix’s 10-year agreement in Europe shows how VBAs are evolving to meet the needs of high-cost, high-impact treatments. Omar and Adam unpack how this deal was structured, why such long-term agreements are gaining traction, and what this means for pipeline therapies in cell and gene.
Covered:
The economics of curative therapies
What makes long-term VBAs viable for both sides
Early signals on payer thinking across the EU
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
